A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Clinical trial NCT05426486 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05426486
- Sponsor
- Caigang Liu
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-23
- Primary completion
- 2025-12-30
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.